galiximab

BIOLOGICAL3 trials

Sponsors

Alliance for Clinical Trials in Oncology, Biogen

Conditions

LymphomaLymphoma, Non-Hodgkin's

Phase 1

Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

TerminatedNCT00651443

BiogenLymphoma, Non-Hodgkin's

Start: 2008-08-31End: 2010-12-31Target: 20Updated: 2011-01-07

Phase 2

Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

CompletedNCT00117975

Alliance for Clinical Trials in OncologyLymphoma

Start: 2005-06-30End: 2013-08-31Updated: 2016-07-06

Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

CompletedNCT00516217

Alliance for Clinical Trials in OncologyLymphoma

Start: 2008-06-30End: 2015-02-28Updated: 2016-07-06

Related Papers

Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance)

Blood2016-12-024 citations